NEX-22 is progressing as expected, with the last patient in Phase I treated, results anticipated lat...
Orders -9%, sales +10% vs. ABGSCe EBIT EUR 3m (vs. ABGSCe 2m), for a margin of 7% Profitability impr...
Adj. EBITA -9% vs ABG and -26% vs cons (one large outlier) 5% organic growth (ABG 8%) vs 1% in Q2 an...
Redeye states that the Q3 report was solid, with ad revenues returning to y/y growth, while recurrin...
Relais Group's Q3 report fell slightly short of LSEG Data & Analytics consensus.
CapMan's Management company business turnover (excluding carried interest) grew 16% y/y in Q3, suppo...
Redeye updates its estimates and valuation following Mentice’s Q3 2024 report.
Redeye provides an update following Optomed’s Q3 report.
Redeye maintains a positive view of Transtema following a softer Q3 than expected due to weak margin...
56% incre. EBITDA margin in Q3 highlights the scalability Increased confidence in positive EBIT in 2...
Ramlösa Shipping (”Ramlösa” eller ”bolaget”) meddelade den 7 november år 2024 att bolaget har förvär...
20% revenue beat driven by high watch sales, EBITDA 66% above Opex was above, but likely due to extr...
Prospekterings- och gruvutvecklingsbolaget Bluelake Minerals bearbetningskoncession för Levi blev go...
Administer’s Q3 report was in line with expectations.
Marimekko’s Q3 brought no real surprises as the net sales were in line with our estimates while prof...
CapMan’s Q3 results were below our and consensus expectations.
After the recent rights issue, Ascelia has SEK 95.
Redeye provides its initial take on Mentice’s Q3 2024 report, which came in broadly below our estima...
Redeye considers Arise’s Q3 2024 report to be in line with our estimates, adjusted for the extra rev...
Redeye provides its initial take on Acarix’s Q3 report, which showed revenues falling short of estim...
